Xponance Inc. Buys 20,030 Shares of Bristol-Myers Squibb (NYSE:BMY)

Xponance Inc. raised its stake in Bristol-Myers Squibb (NYSE:BMY) by 7.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 277,469 shares of the biopharmaceutical company’s stock after acquiring an additional 20,030 shares during the quarter. Xponance Inc.’s holdings in Bristol-Myers Squibb were worth $14,237,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. OFI Invest Asset Management bought a new position in shares of Bristol-Myers Squibb in the third quarter worth about $25,000. True Wealth Design LLC bought a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $26,000. Milestone Investment Advisors LLC bought a new position in Bristol-Myers Squibb in the 3rd quarter valued at approximately $27,000. Coppell Advisory Solutions LLC bought a new position in Bristol-Myers Squibb in the 2nd quarter valued at approximately $28,000. Finally, Blue Bell Private Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 200 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on BMY. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. Finally, Bank of America downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the company from $68.00 to $60.00 in a research report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $61.18.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY remained flat at $48.30 during midday trading on Friday. The stock had a trading volume of 933,790 shares, compared to its average volume of 15,585,065. Bristol-Myers Squibb has a 52 week low of $47.58 and a 52 week high of $70.93. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $97.89 billion, a P/E ratio of 12.51, a price-to-earnings-growth ratio of 1.44 and a beta of 0.39. The firm has a 50-day moving average price of $51.25 and a two-hundred day moving average price of $51.57.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.55 by $0.15. The company had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. Bristol-Myers Squibb’s revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.82 earnings per share. Equities analysts expect that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 4.97%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.